Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.60 |
| ▸ | DRD2 | P14416 | 10/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 6/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824367 | 0.89 | DRD4 (0.56) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4822287 | 0.81 | DRD4 (0.62) | DRD4DRD2DRD3HTR1A | |
| SCHEMBL4822169 | 0.79 | DRD4 (0.63) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4823457 | 0.78 | DRD4 (0.65) | DRD4DRD2DRD3HTR1A | |
| SCHEMBL30040776 | 0.78 | DRD4 (0.61) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL23964191 | 0.78 | DRD4 (0.61) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL857986 | 0.77 | DRD2 (0.66) | DRD4DRD2DRD3HTR1A | |
| SCHEMBL5379237 | 0.76 | DRD4 (0.67) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4825047 | 0.75 | HTR1A (0.59) | DRD4DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4807109 | 0.75 | DRD4 (1.00) | DRD4DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | claimed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | claimed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | claimed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | claimed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | claimed |
| US-7470691-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | DRD4 1401/4885DRD2 1129/4885DRD3 1050/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | DRD4 102/4885DRD2 66/4885DRD3 81/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | DRD4 100/4885DRD2 63/4885DRD3 85/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | DRD4 1401/4885DRD2 1129/4885DRD3 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.